JSC Responsibilities Sample Clauses
JSC Responsibilities. The JSC shall be responsible for overseeing and managing the collaboration with respect to Cell Therapy Products and Collaboration Products, including, without limitation the following functions:
(A) The JSC shall meet at least twice per Calendar Year. Such meetings shall alternate between Amgen and ViaCell locations and be held at such times as are agreed upon by the JSC. At least one JSC meeting per year shall be conducted in person, whereas other JSC meetings may be held in person or by video conference or teleconference. The first meeting shall be held at Amgen's facilities within [**] of the Effective Date, and the agenda for such meeting shall include a review of a program plan for 2004 including a budget for Direct Development Costs for CB001 and any other Cell Therapy Products. If a Party's representative is unable to attend a meeting, such Party may designate an alternate representative to attend such meeting. In addition, each Party may, at its discretion (and with the consent of the other Party, not to be unreasonably withheld), invite additional employees, consultants or scientific advisors to attend any JSC meetings.
(B) The JSC shall review and discuss the progress of ViaCell's Development and manufacturing of Cell Therapy Products and, if applicable, Amgen's Development and Commercialization and ViaCell's manufacturing of Collaboration Products, including review of plans, budgets, clinical trial designs, data, results and other information in appropriate detail to enable the JSC members to meaningfully monitor the progress of the Development, manufacturing and Commercialization efforts of the Parties and to provide advice and feedback relating thereto.
(C) The JSC shall consider the applicability and usefulness of any Materials that a Third Party or Amgen may (in its sole discretion) choose to make available to ViaCell for use in producing or using the Cell Therapy Products and/or the Collaboration Products.
(D) Each year at the first JSC Meeting after the beginning of ViaCell's fiscal year the JSC shall review an annual budget for projected Direct Development Costs for each Cell Therapy Product for the following year prepared by ViaCell in conjunction with ViaCell's annual budget process. At the first JSC meeting after the end of ViaCell's fiscal year, the JSC shall review and reconcile the actual Direct Development Costs for each Cell Therapy Product to the budget previously reviewed. Upon approval by the JSC of the budget and the reconcil...
JSC Responsibilities. The JSC shall perform the following functions:
(1) without prejudice to Clause 5.1(C)(3), at least [***] throughout the Term of this Agreement, review and discuss strategies and detailed plans (and progress against such plans) for the Development and Manufacture of Licensed Product in the Field and any Substantive Amendments (as defined below) to any such plans, as well as a more high-level review and discussion of the Commercialisation Plan;
(2) review and discuss the high-level budgeted costs for Development and Manufacturing and actual spendings against such budgeted costs for each Calendar Quarter;
(3) approve [***] the Development Plan, Manufacturing Plan and Technology Transfer Plan and (to the extent provided in this Agreement) any Commercialisation Plan for the subsequent Calendar Year, including budget and timelines, and subsequently during such Calendar Year approve any proposed Substantive Amendments to such plans;
(4) discuss and approve any extension of any of the Development Diligence Milestone deadlines provided for in Clauses 4.3(A)(1) and 4.3(A)(2), or any suspension of any Development Diligence Milestone as provided for in Clause 4.3(A)(4);
(5) discuss and approve any proposal to Develop the [***] and the Development Plan for such [***];
(6) discuss and determine the need for any Third Party IPR licences, as provided for in Clause 6.8;
(7) discuss and approve the need to use any platform technologies Controlled by Genmab, as set out in Clause 1.64, for the Development or Commercialisation of Licensed Product as contemplated in this Agreement;
(8) discuss and approve [***];
(9) discuss and approve [***]
(10) appoint sub-committees as appropriate to facilitate coordination and cooperation between the Parties or otherwise to further the purposes of this Agreement [***];
(11) discuss any dispute between the Parties as to whether a milestone payment has been triggered;
(12) serve as the first forum for the settlement of disputes or disagreements that are unresolved by the Development Committee, unless otherwise indicated in this Agreement;
(13) discuss and approve any proposed extension of the Development Committee Term;
(14) review and approve any Development Costs in excess of [***] percent [***]%) prior to payment in accordance with Clause 5.4(A); and
(15) perform such other functions as appropriate to further the purposes of this Agreement as determined by the Parties. For the purposes of the foregoing:
(i) the term “Substantive Amendment”...
JSC Responsibilities. The JSC shall be responsible for (a) reviewing the progress of the Development and ensuring that the Development commences and proceeds according to the Development Plan; (b) coordinating the Development and Commercialization activities under the Development Plan and Commercialization Plan; (c) discussing and suggesting amendments to the Development Plan and Commercialization Plan to a higher decision level for both Parties; (d) exchanging information related to publication strategies and review of such information; (e) resolving issues or disagreements raised by the JCC, JPT or JPT Leads, subject to final approval by the Parties; (f) facilitating the transfer of information and data related to development, Commercialization and Regulatory Approval processes or other processes for completing activities respecting the Development Plan and Commercialization Plan; (g) facilitating the cooperation of the Parties, when requested, to provide information and support; (h) facilitating coordinated interpretation of Clinical Data and other Data; (i) discussing freedom to operate aspects and issues; (j) coordinating planned marketing activities; and (k) such other activities pertaining to the Development and Commercialization activities ascribed to the JSC in this Agreement or as mutually agreed between the Parties from time to time (including the formation or disbandment of any subcommittees (e.g., the JPT or JCC). The JSC shall keep accurate and complete confidential minutes of its meetings. The co-chairs for each meeting, or their respective designees, shall be responsible for taking such minutes and distributing a coordinated single draft agreed upon by the co-chairs to the other JSC members for their review and comment within [***] Business Days after the date of each meeting. The JSC members shall in good faith attempt as quickly as is reasonably possible to resolve any disputes as to the content of such minutes so as to have a final agreed version as quickly as is reasonably possible, but no later than [***] Business Days after the dispute is raised. Each of BTO and ▇▇▇▇▇▇▇ shall be responsible for all expenses incurred by its representatives on the JSC in connection with performing their duties hereunder, including all costs of travel, lodging and meals. For the avoidance of doubt, the JSC shall not have the authority to amend this Agreement and shall have authority to amend the Development Plan and Commercialization Plan only as expressly set forth herein, o...
JSC Responsibilities. The JSC will have oversight and information sharing responsibilities and functions with respect to the worldwide Development, Manufacture, Commercialization, and other Exploitation of the Products. The JSC will, amongst other duties and responsibilities:
i) [***];
ii) [***];
iii) [***]; and
iv) [***].
JSC Responsibilities. The JSC shall oversee the Development, and Commercialization of the Licensed Products in the Licensed Territory. In particular, the JSC shall:
(i) serve as a forum for sharing information, including receiving Development Reports and any additional reports, including any serious adverse event report, for Licensed Drug Substance and Licensed Product in the Licensed Field in the Licensed Territory;
(ii) review and serve as a forum for discussing plans and budgets, including the Joint Development Plan and Commercialization Plan and review amendments thereto;
(iii) coordinate and review any material safety and quality issues regarding the Licensed Drug Substance and Licensed Product in the Licensed Territory;
(iv) create and oversee any subcommittees or working groups as the JSC may deem appropriate; and
(v) perform such other functions as are set forth herein or as the Parties may mutually agree in writing, except where in conflict with any provision of this Agreement.
JSC Responsibilities. The JSC shall serve as a forum for the Parties to share information regarding the Development, Manufacture, and Commercialization of the Compound and/or Products in the Field in the Territory and to facilitate coordination between the Parties, but shall not have any decision-making authority with respect to the Parties’ activities under this Agreement. Additionally, Evommune shall share information relating to the Development and Commercialization of the Product outside of the Territory to the extent necessary or useful for Maruho to Develop, Manufacture, and/or Commercialization the Compound and any Product in the Field in the Territory.
JSC Responsibilities. The JSC shall have the following responsibilities with respect to the Technology Collaboration:
1. oversight of all activities relating to the Technology Collaboration;
JSC Responsibilities. Responsibilities of the JSC shall be the following:
(i) Discussing and reviewing the development and regulatory strategies and activities for the Licensed Products in and outside the Territory and, to the extent reasonably possible, coordinating strategies in and outside the Territory;
(ii) Discussing and reviewing the commercialization strategies and activities of the Licensed Products in and outside the Territory and, to the extent reasonably possible, coordinating strategies in and outside the Territory;
(iii) Discussing and reviewing the matters relating to supply that are not specifically addressed within the Supply Agreement of the Licensed Products by BIAL to NBIX for use hereunder;
(iv) Discussing, reviewing and approving the Development and Regulatory Plan and amendments thereto prior to adoption or implementation thereof;
(v) Discussing, reviewing and approving the Annual Commercialization Plan, and updates or amendments thereto prior to adoption or implementation thereof;
(vi) Reporting on the status of ongoing Development Studies and other development activities with respect to Licensed Products in the Field in and, to the extent BIAL has the right to disclose them, outside the Territory;
(vii) Reporting on the status of ongoing commercial activities with respect to Licensed Products in the Field in and, to the extent BIAL has the right to disclose them, outside the Territory;
(viii) Reviewing and agreeing the Agreed Sales Forecast;
(ix) Resolving disputes in respect of proposed publications in accordance with Section 9.3; and
(x) Performing such other responsibilities as may be assigned to the JSC pursuant to this Agreement or as may be mutually agreed upon in writing by the Parties from time to time.
JSC Responsibilities. The JSC shall be responsible for: (i) reviewing each Party’s Business Plan; (ii) reviewing progress of LifeCell marketing activities and Novadaq research and development activities; (iii) reviewing all Device specifications and clinical study plans and schedules; (iv) attempting to resolve disputes, if any; and (v) performing such other tasks and undertaking such other responsibilities to which the Parties may jointly agree. The JSC shall only act unanimously and each of LifeCell and Novadaq, acting through its representatives, shall have one vote on the JSC. If the JSC is unable to agree on any issue, the JSC may escalate such issue to the President of LifeCell and CEO of Novadaq respectively for resolution. If the issue remains unresolved sixty (60) days after the Parties agree to escalate to the President of LifeCell and CEO of Novadaq, or their respective designee, then the dispute shall be settled by the Section 22.12 herein (Dispute Resolution).
JSC Responsibilities. During the Term, the JSC shall:
(i) Determine whether **** of the Collaboration Work Plan ****;
(ii) Amend the Collaboration Work Plan to include additional experiments, if desired by both parties, provided that, if such amendments require additional financial consideration from ▇▇▇▇▇▇▇ or additional activities by Genocea, the parties must amend this Agreement in writing; and
(iii) Attempt to resolve any disputes on an informal basis.
